2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002

Vasogen to Conduct Year-end Conference Call

Toronto, Ontario - January 13, 2005

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular and neurological disease, will release its fourth quarter and year-end results after the close of the North American financial markets on Tuesday, January 18, 2005. A conference call will follow at 4:30 p.m. Eastern Time, during which management will provide a company update and discuss year-end results. Participants are invited to attend by connecting 10 minutes prior to the call to one of the following:

Audio Web Cast*	www.vasogen.com
Direct Dial	416-695-5261
Toll-free	1-888-789-0150

A re-broadcast of the conference call may be accessed by:

Audio Web Cast*	www.vasogen.com
Direct Dial	1-866-631-6903 Pin code: 1247

Windows Media Player required*

About Vasogen
Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Vasogen’s lead product, Celacade™ (immune modulation therapy) is currently in pivotal phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. The Company’s 2,000-patient ACCLAIM trial, being conducted at cardiac centers throughout North America and Europe, is investigating the impact of Celacade™ on reducing the risk of mortality and morbidity in advanced chronic heart failure patients. Vasogen’s 500-patient SIMPADICO trial, being conducted at medical centers throughout North America, is designed to further investigate the impact of Celacade™ on reducing the debilitating symptoms associated with peripheral arterial disease. Celacade™ is designed to target chronic inflammation by activating the immune system’s physiological anti-inflammatory response to apoptotic cells. Vasogen is also developing a new class of drugs designed to interact with immune cells leading to the modulation of cytokines – potent chemical messengers that regulate and control inflammation. VP025, the lead product candidate from this new class of drugs, is in preclinical development for the treatment of neurodegenerative disorders including Parkinson’s and Alzheimer’s disease.